|Bid||9.23 x 800|
|Ask||9.28 x 1000|
|Day's Range||9.23 - 9.61|
|52 Week Range||4.78 - 14.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2017 - May 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a Phase 2/3 trial of MN-166 (ibudilast) in degenerative cervical myelopathy (DCM) in collaboration with the University of Cambridge. This clinical trial is being conducted under an agreement between MediciNova, the University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust.
The oral presentation entitled "Novel Composite Endpoint Extended Analysis during Extension of Ibudilast Phase 1b/2a Clinical Trial Better Predicts Post-Wash-Out Survival” will be given by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing biomarker clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) is now fully enrolled with 35 subjects. This trial will measure the effect of MN-166 (ibudilast) on reducing brain microglial activation measured by positron emission tomography (PET) imaging using a biomarker and will also evaluate clinical outcomes in ALS subjects. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that this study is now fully enrolled.
On July 23, 2018, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2018. As expected, the company did not report any revenues. The increase in R&D expenses was primarily due to increased clinical trial costs for MN-166.
This group was comprised of 31 subjects out of a total of 49 subjects in the full analysis set. A second subgroup comprised of 39 subjects (out of a total of 67 subjects in the full analysis set) who had either bulbar onset or upper limb onset ALS with or without NIV (the “Early ALS + NIV subgroup”). The score is utilized to keep track of the health of all ALS patients, and is a common outcome measure in ALS clinical trials.
The ad-hoc subgroup analyses include data from (1) the “Early ALS subgroup” which is 31 subjects who had either bulbar onset or upper limb onset out of a total of 49 subjects without non-invasive ventilation in the full analysis set and (2) the “Early ALS + NIV subgroup” which is 39 subjects who had either bulbar onset or upper limb onset out of a total of 67 subjects with and without non-invasive ventilation in the full analysis set. The full analysis set includes all randomized subjects who received at least 14 days of study drug and had at least one post-dose efficacy measurement.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia and hypercholesterolemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.
NEW YORK, June 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Galapagos ...
MediciNova Inc’s (NASDAQ:MNOV): MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in theRead More...
After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...
MediciNova, Inc. (MNOV) recently had additional data presented on one of its lead compounds, MN-166 (ibudilast), in two different indications at the American Academy of Neurology (AAN) 70th Annual Meeting. Progressive Multiple Sclerosis (MS): Dr. Robert Fox, the principal investigator of the completed Phase 2 SPRINT-MS trial, gave a presentation titled “A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis”. Included in the presentation was the previously announced data showing that treatment with MN-166 resulted in a 48% reduction in the rate of whole brain atrophy progression.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Financial Select Sector SPDR Fund (NYSE: XLF ) stock ...
Here's a few must-watch biotech catalysts this week . Conferences Panamerican League of Associations for Rheumatology Congress – April 7-11 at Hotel Hilton, Buenos Aires, Argentina. The International Liver ...
Stock Monitor: AC Immune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on MediciNova, Inc. (NASDAQ: MNOV ). If you want ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...